CA Patent

CA2679126A1 — Macrocyclic compound

Assigned to Chugai Pharmaceutical Co Ltd · Expires 2008-09-04 · 18y expired

What this patent protects

Disclosed is a new class of compound which has HSP90 inhibitory activity and is useful as an antitumor agent or the like. Also disclosed is a compound which is useful as a synthesis intermediate for the compound having HSP90 inhibitory activity. Specifically disclosed is a compou…

USPTO Abstract

Disclosed is a new class of compound which has HSP90 inhibitory activity and is useful as an antitumor agent or the like. Also disclosed is a compound which is useful as a synthesis intermediate for the compound having HSP90 inhibitory activity. Specifically disclosed is a compound represented by the general formula (1) below, or a pharmaceutically acceptable salt thereof. (In the formula, X, R1, R2, R3, R4, R5, R6, R7, L1, L2 and L3 are as defined in the description.)

Drugs covered by this patent

Patent Metadata

Patent number
CA2679126A1
Jurisdiction
CA
Classification
—
Expires
2008-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Chugai Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.